Table 4.
Sleep measures on screening and the three discontinuation nights ofmonths 1, 4, and 12.
| Placebo |
Zolpidem |
|||||||
|---|---|---|---|---|---|---|---|---|
| Scrn | Discon1 | Discon2 | Discon3 | Scrn | Discon1 | Discon2 | Discon3 | |
| Month 1 | ||||||||
| TST | 350.80 (44.87) |
385.1 (47.17) |
361.3 (83.48) |
383.5 (66.20) |
358.2 (50.47) |
380.0 (66.29) |
408.0 (38.75) |
396.0 (53.81) |
| LPS | 42.65 (38.85) |
19.03 (19.37) |
26.80 (30.63) |
30.38 (31.22) |
45.18 (37.95) |
25.53 (24.58) |
21.94 (12.89) |
15.25 (15.18) |
| WASO | 104.9 (45.77) |
81.65 (44.27) |
82.60 (42.34) |
80.41 (51.70) |
100.9 (40.88) |
80.68 (55.56) |
58.00 (35.57) |
74.47 (55.17) |
| Month 4 | ||||||||
| TST | 350.8 (44.87) |
359.37 (75.98) |
355.6 (80.45) |
382.03 (47.18) |
358.2 (50.47) |
384.6 (58.55) |
407.9 (439.79) |
395.91 (76.05) |
| LPS | 42.65 (38.85) |
31.53 (29.97) |
34.60 (43.07) |
47.81 (104.89) |
45.18 (37.95) |
29.00 (22.73) |
28.22 (30.23) |
39.81 (61.15) |
| WASO | 104.9 (45.77) |
97.53 (56.17) |
106.9 (79.73) |
84.44 (49.49) |
100.9 (40.88) |
82.22 (50.90) |
49.78 (24.12) |
56.66 (47.58) |
| Month 12 | ||||||||
| TST | 350.8 (44.87) |
376.1 (71.16) |
374.8 (54.24) |
355 (90.20) |
358.2 (50.47) |
373.03 (67.27) |
377.5 (66.45) |
414.56 (42.53) |
| LPS | 42.65 (38.85) |
36.85 (65.79) |
25.59 (26.80) |
37.03 (45.92) |
45.18 (37.95) |
29.59 (39.02) |
26.53 (31.01) |
17.34 (13.18) |
| WASO | 104.9 (45.77) |
81.09 (51.76) |
88.68 (40.30) |
100.49 (73.33) |
100.9 (40.88) |
94.16 (59.92) |
80.18 (56.74) |
54.66 (36.80) |
Data means (SD) in minutes. For comparison purposes the screening data shown for month 1 are repeated at month 4 and 12. Comparing across columns within a row, total sleep times less than screening and latency to persistent sleep and wake during sleep times greater than screening would reflect rebound insomnia. Discon, discontinuation night; LPS, latency to persistent sleep; Scrn, screen night; TST, total sleep time; WASO, wake after sleep onset.